GSK/Abbott Pen Rx/Dx Co-Development Deal for MAGE-A3 Non-Small Cell Lung Cancer Treatment
July 15, 2009
GSK/Abbott Pen Rx/Dx Co-Development Deal for MAGE-A3 Non-Small Cell Lung Cancer Treatment
GSK and Abbott will develop a companion diagnostic for GSK's investigational MAGE-A3 immunotherapy. After discussions with the FDA, GSK believes the drug and diagnostic will be reviewed simultaneously, and labeling language for the drug will require genetic testing prior to treatment.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pfizer, Abbott Ink Deal to Develop Companion Dx for PGx-based NSCLC Drug
September 2, 2009 / Pharmacogenomics Reporter - Abbott, GSK Add New Biomarker to Cancer Immunotherapy Companion Dx Agreement
December 1, 2011 / PCR Insider - Life Tech and GSK to Co-Develop qPCR-Based Companion Dx for Investigative Cancer Immunotherapy
October 27, 2011 / PCR Insider - Abbott, GSK Extend MAGE-A3 Companion Dx Collaboration into Skin Cancer
March 10, 2010 / Pharmacogenomics Reporter - Abbott, GSK to Develop PCR-Based Molecular Dx to Select Patients for Trial Skin Cancer Therapy
March 4, 2010 / PCR Insider